LDS/Medical Tests/Cytochrome P450 3A5 (CYP3A5) Genotyping

Cytochrome P450 3A5 (CYP3A5) Genotyping

Cytochrome P450 (CYP) represents a large superfamily of enzymes catalyzing oxidation of organic substances. CYP enzymes are integral in metabolizing both endogenous and exogenous substances, which include intermediates of lipids and steroidal hormones, drugs and toxic chemicals.

CYP3A, a subfamily of CYP450, consists of 4 genes CYP3A4, CYP3A5, CYP3A7, and CYP3A43. The substrates of the CYP3A subfamily constitute half of the drugs that are metabolized oxidatively by the CYP superfamily. Together, they help facilitate the elimination of 37% of the 200 most frequently prescribed drugs in the U.S. In adults, CYP3A4 and CYP3A5 are metabolically active and constitute approximately 30% of CYP activity. CYP3A5 expression is highly polymorphic. To date, there are 25 allelic variants of CYP3A5 (alleles numbered *1–*9).

Alleles CYP3A5 *1 and CYP3A5 *3 are distributed widely across various geographical and ethnic groups. CYP3A5 *1 represents a functional CYP3A5 while CYP3A5 *3 represents the most common non-functional variant which results in an enzyme with no activity. The CYP3A5 *3B and *6 are also null alleles resulting also in no enzyme activity. The CYP3A5 alleles *2, *8 and *9 result in an enzyme that is partially active. Individuals with CYP3A5 *1/*1 and *1/*3 genotypes express CYP3A5 and hence metabolize the substrates more rapidly than CYP3A5 *3/*3 genotype and other non-expressers. Clinically important substrates include tacrolimus (immunosuppressive drug used in organ transplantation), midazolam, saquinavir (anti-retroviral drug), vincristine (mitotic inhibitor) and the statin group of drugs. The CYP3A5 enzyme activity influences the therapeutic dosing and dose-dependent adverse reactions of these substrates.

CYP3A5 variations have been associated with certain disease states including malignancies such as acute lymphoid leukemia and chronic myeloid leukemia.

  • Determining therapeutic strategy for therapeutics that are metabolized by the CYP3A5 gene product (antidepressant and other metabolized drugs)
  • Monitor and manage tacrolimus and statin drug therapy
  • Monitor and manage pain management drug therapy
  • As an aid in therapy of prostate cancer and leukemias
  • If genotype CYP3A5 *1/*1 or *1/*3 or *1 other alleles are detected, this would be reported as normal to intermediate metabolizer
  • If genotype CYP3A5 *3/*3 is detected, or if CYP3A5 *1 allele is NOT detected, this would be reported as a poor metabolizer

The following is a list of major therapeutic classes with drugs that are substantially metabolized by CYP3A.

Statins: atorvastatin, simvastatin, lovastatin.

Calcium channel blockers: nifedipine, verapamil, nicardipine, felodipine, nisoldipine.

Antiplatelets: clopidogrel, prasugrel, ticagrelor, cilostazol.

Antiarrhythmics: amiodarone, quinidine, disopyramide, lidocaine.

Example of angina treatments: ranolazine.

Angiotensin II Inhibitors: losartan.

Anticoagulants: rivaroxaban, apixaban.

The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.

A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole,nefazodone, saquinavir, telithromycin

A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include: aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem

A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance such as cimetidine, amiodarone, chloramphenicol, boceprevir, ciprofloxacin, delaviridine, diethyl, dithiocarbamate, fluvoxamine, gestodene, imatinib, mibefradil, mifepristone, norfloxacin, norfluoxetine, starfruit, telaprevir, voriconazole

CYP3A5 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices, buccal swab, saliva. 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Therapeutic drug monitoring is the standard of care for monitoring patients on tacrolimus. Drug toxicity tests and clinical assessments are recommended for other drugs; other CYP enzymes such as CYP2D6, CYP2C19, and CYP2C9.
3-5 days.
No CPT CodesNo Fees
Showing results for CA - California - Entire State.
Filter:
ICD10 Code and DescriptionLCD CodeNCD Code
No results found matching your search criteria.
Showing results for CA - California - Entire State.
Filter:
ICD10 Code and DescriptionLCD CodeNCD Code
No results found matching your search criteria.